Oregon Health & Science University researchers reported that combining the BCL2 inhibitor venetoclax with the CDK4/6 inhibitor palbociclib produced stronger, more durable anti‑leukemia responses in AML patient samples and mouse xenografts. The Cell Reports Medicine study screened 25 combinations across more than 300 patient samples and found venetoclax+palbociclib the most effective in overcoming common resistance mechanisms. Mechanistic work showed co‑targeting of cell‑cycle and protein‑synthesis pathways and evidence of mitigated adaptive resistance compared with single agents. The team argues the regimen merits rapid clinical evaluation given venetoclax’s frontline use and the unmet need created by near‑universal relapse. Clarification: venetoclax targets the anti‑apoptotic protein BCL2; palbociclib blocks CDK4/6‑driven cell‑cycle progression, and their combination aims to force leukemic cells into apoptosis.